Zai Lab Presents Positive Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) at Society of Gynecologic Oncology Meeting

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Related Keywords

China ,Shanghai ,Cambridge ,Cambridgeshire ,United Kingdom ,Peking ,Beijing ,Hong Kong ,Macau ,Chinese ,Alan Sandler ,Ron Aldridge ,Alina Zhang ,Lingying Wu ,Danielle Halstrom Xiaoyu Chen ,Glaxosmithkline ,Zai Lab ,Zai Lab Limited ,Nasdaq ,Zai Laboratory ,China National Medical Products Administration ,National Healthcare Security Administration ,Zai Lab Forward ,Society Of Gynecologic Oncology ,National Cancer Center Clinical Research ,Union Medical College ,Department Of Gynecologic Oncology ,Exchange Commission ,Hong Kong Department Of Health ,National Reimbursement Drug List ,Chinese Academy Of Medical Sciences ,Head Of Global Development ,Lab Limited ,Gynecologic Oncology ,Global Development ,National Cancer Center ,National Clinical Research Center ,Cancer Hospital ,Chinese Academy ,Medical Sciences ,Peking Union Medical ,New Drug Application ,Hong Kong Department ,Private Securities Litigation Reform Act ,Danielle Halstrom ,Xiaoyu Chen ,Coronavirus Pandemic ,Business ,Health ,Globe Newswire ,